Cure Sma
Based in IL
🤖
AI Overview
With $2.0M in lobbying spend across 36 quarterly filings, Cure Sma is a significant lobbying presence. Their lobbying covers 14 issue areas. Active from 2018 to 2025.
$2.0M
Total Spend
8
Years Active
1
Firms Hired
5
Lobbyists Deployed
14
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $170K |
| 2019 | $410K |
| 2020 | $140K |
| 2021 | $140K |
| 2022 | $230K |
| 2023 | $300K |
| 2024 | $300K |
| 2025 | $300K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Health Issues, Education, Transportation, Unemployment and 9 more
- •Federal funding for newborn screening, biomedical research
- •Newborn screening for genetic conditions
- •Biomedical research and drug development
- •Access to care, insurance coverage
Related Analysis
📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders
🏭 Defense Lobbying
Industry overview and top spenders
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Lobbying vs. Federal Contracts
How lobbying spending correlates with contract awards.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.